FDA Approves Controversial New Opioid

FDA Approves Controversial New Opioid

The FDA has approved a pill version of a powerful opioid previously only available intravenously, and critics say the decision will allow some people to abuse the drug.

Dsuvia, a tablet that is placed under the tongue, contains the synthetic opioid sufentanil, which is considered five to 10 times more powerful than fentanyl, a synthetic opioid that has led to fatal overdoses, and 500 times more powerful than morphine. Because Dsuvia is so powerful, the drug is only intended for use in hospitals and surgical centers. The FDA also noted that the drug serves a military purpose for battlefield wounds when intravenous administration of sufentanil isn’t possible.

Although the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee last month overwhelmingly voted in favor of approving Dsuvia, its chairman, Raeford Brown, MD, a professor of anesthesiology and pediatrics at the University of Kentucky, was not present. After the meeting, Brown sent a letter to the FDA asking them to reject Dsuvia.

“I predict that we will encounter diversion, abuse, and death within the early months of its availability on the market,” Brown wrote in the letter.

FDA Commissioner Scott Gottlieb said in a statement that as part of Dsuvia’s approval, precautions have been taken to minimize the risk of its being abused. Dsuvia will only be available in “certified medically-supervised health care settings,” should not be used for more than three days and can’t be prescribed for patients to take at home.

He added that Dsuvia is reserved for patients who have tried other pain medications and failed or are expected to fail on them.


Jonathan Block

Jonathan Block

Jonathan Block is an associate editor at BioCentury, which provides news and information about the biotechnology and pharmaceutical industries. Prior to joining BioCentury in 2019, Jonathan worked for MedShadow as content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.


Did you find this article helpful?

No votes so far! Be the first to rate this post.


Latest News

Belviq, ActiPatch, Free Samples, Dollar Tree Drugs

Belviq, ActiPatch, Free Samples, Dollar Tree Drugs

We knew it was too good to be true – free and cheap drugs aren’t worth it. Also, taking a magic pill to lose weight could give you cancer (!). One ray of sunshine: a pain therapy device using shortwave is now available over-the-counter. Have a lovely Valentine’s Day! Be…

Flouride, PPIs, Breast Density and Prostate Cancer

Flouride, PPIs, Breast Density and Prostate Cancer

Startling news about fluoride, a study encourages more limites use of PPIs, does knowing the density of your breasts matter, and vegetables aren’t helpful in warding off prostate cancer (darn).  Be Well.  Fluoride and Pregnancy The medical community was shocked at the conclusions of two new studies on fluoride’s effect…

  • Advertisement